Nurix Therapeutics Inc. (NRIX)
10.24
0.44 (4.49%)
At close: Apr 17, 2025, 3:59 PM
10.65
4.01%
Pre-market: Apr 21, 2025, 08:09 AM EDT
4.49% (1D)
| Bid | 9.5 |
| Market Cap | 780.65M |
| Revenue (ttm) | 56.42M |
| Net Income (ttm) | -208.4M |
| EPS (ttm) | -2.79 |
| PE Ratio (ttm) | -3.67 |
| Forward PE | -3.02 |
| Analyst | Buy |
| Ask | 10.67 |
| Volume | 1,322,026 |
| Avg. Volume (20D) | 915,424 |
| Open | 9.65 |
| Previous Close | 9.80 |
| Day's Range | 9.54 - 10.26 |
| 52-Week Range | 8.18 - 29.56 |
| Beta | 2.24 |
About NRIX
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malig...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 286
Stock Exchange NASDAQ
Ticker Symbol NRIX
Website https://www.nurixtx.com
Analyst Forecast
According to 17 analyst ratings, the average rating for NRIX stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 202.73% from the latest price.
Stock Forecasts4 months ago
+6.78%
Nurix Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
4 months ago
+6.53%
Nurix Therapeutics shares are trading higher after BMO Capital initiated coverage on the stock with an Outperform rating and announced a price target of $35.
